Drug delivery systems for infection: Liposome-incorporating antimicrobial drugs

Journal of Infection and Chemotherapy

Volumn 4, Issue 4, 1998, Pages 159-173

  Kohno, Shigeru ^a   Tomono, Kazunori ^a   Maesaki, Shigefumi ^a  

^a NAGASAKI UNIVERSITY   (Japan)

Author keywords

Antibiotics; Antifungal agents; Drug delivery system; Drug resistance; Immunoliposomes; Intracytoplasmic pathogen; Liposomes; Site avoidance delivery; Targeting therapy

Indexed keywords

EID: 27144485836     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02490162     Document Type: Review

References (85)

1. Nacucchio MC, Gatti Bellora MJ, Sordelli DO, D'Aquino M. Enhanced liposome-mediated activity of piperacillin against staphylococci. Antimicrob Agents Chemother 1985;27:137-139.
2. Nacucchio MC, Gatti Bellora MJ, Sordelli DO, D'Aquino M. Enhanced liposome-mediated antibacterial activity of piperacillin and gentamicin against gram-negative bacilli in vitro. J Microencapsul 1988;5:303-309S.
3. Lagace J, Dubreuil M, Montlaisir S. Liposome-encapsulated antibiotics: preparation, drug release and antimicrobial activity against Pseudomonas aeruginosa. J Microencapsul 1991;8:53-61.
4. Al-Awadhi H, Stokes GV, Reich M. Inhibition of Chlamydia trachomatis growth in mouse fibroblasts by liposome-encapsulated tetracycline. J Antimicrob Chemother 1992; 30:303-311.
5. Schentag JJ. Antimicrobial kinetics and tissue distribution: concepts and applications. In: Ristuccia AM, Cunha BA (eds) Antimicrobial therapy. New York: Raven Press, 1984:81-93.
6. Koga H. High-performance liquid chromatography measurement of antimicrobial concentrations in polymorphonuclear leukocytes. Antimicrob Agents Chemother 1987; 31:1904-1908.
7. Ishiguro M, Koga H, Kohno S, Hayashi T, Yamaguchi K, Hirota M. Penetration of macrolides into human polymorphonuclear leucocytes. J Antimicrob Chemother 1989; 24:719-729.
8. Desiderio JV, Campbell SD. Intraphagocytic killing of Salmonella typhimurium by liposome-encapsulated cephalothin. J Infect Dis 1983;148:563-570.
9. Tadakuma T, Ikewaki N, Yasuda T, Tsutsumi M, Saito S, Saito K. Treatment of experimental salmonellosis in mice with streptomycin entrapped in liposomes. Antimicrob Agents Chemother 1985;28:28-32.
10. Bakker-Woudenberg IAJM, Lokerse AF, Vink-Van Den Berg JC, Roerdink FH, Michel MF. Effect of liposome-entrapped ampicillin on survival of Listeria monocytogenes in murine peritoneal macrophages. Antimicrob Agents Chemother 1986;30:295-300.
11. Bakker-Woudenberg IAJM, Lokerse AF, Roerdink FH, Regts D, Michel MF. Free versus liposome-entrapped ampicillin in treatment of infection due to Listeria monocytogenes in normal and athymic (nude) mice. J Infect Dis 1985;151: 917-924.
12. Kesavalu L, Goldstein JA, Debs RJ, Duzgunes N, Gangadharam PRJ. Differential effects of free and liposome encapsulated amikacin on the growth of Mycobacterium avium complex in mouse peritoneal macrophages. Tubercle 1990;71:215-218.
13. Duzgunes N, Perumal VK, Kesavalu L, Goldstein JA, Debs RJ, Gangadharam PRJ. Enhanced effect of liposome-encapsulated amikacin on Mycobacterium avium-M. intracellulare complex in beige mice. Antimicrob Agents Chemother 1988;32:1404-1411.
14. Klemens SP, Cynamon MH, Swenson CE, Ginsberg RS. Liposome-encapsulated gentamicin therapy of Mycobacterium avium complex infection in beige mice. Antimicrob Agents Chemother 1990;34:967-970.
15. Tomioka H, Saito H, Sato K, Yoneyama T. Therapeutic efficacy of liposome-encapsulated kanamycin against Mycobacterium intracellulare infection induced in mice. Am Rev Respir Dis 1991;144:575-579.
16. Duzgunes N, Ashtekar DR, Flasher DL, Ghori N, Debs RJ, Friend DS, et al. Treatment of Mycobacterium avium-intracellulare complex infection in beige mice with free and liposome-encapsulated streptomycin: role of liposome type and duration of treatment. J Infect Dis 1991;164:143-151.
17. Koga H, Miyazaki Y, Kohno S, Hara K. A drug delivery system and biological modifiers for the treatment of mycobacterial infection. Tuberculosis 1993;69:55-60.
18. Saito H, Tomioka H. Therapeutic efficacy of liposome-entrapped rifampin against Mycobacterium avium complex infection induced in mice. Antimicrob Agents Chemother 1989;33:429-433.
19. Roesler J, Hockertz S, Vogt B, Lohmann-Mathes ML. Staphylococci surviving intracellularly in phagocytes from patients suffering from chronic granulomatous disease are killed in vitro by antibiotics encapsulated in liposomes. J Clin Invest 1991;88:1224-1229.
20. Allen TM, Chonn A. Large unilamellar liposomes with low uptake into the reticuloendothelial system. FEBS Lett 1987;223:42-46.
21. Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphipathic polyethylene glycols effectively prolong the circulation time of liposome. FEBS Lett 1990;268:235-237.
22. Klibanov AL, Maruyama K, Becherleg AM, Torchilin VP, Huang L. Activity of amphipathic polyethylene glycol 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target. Biochim Biophys Acta 1991;1062:142-148.
23. Connor J, Sullivan S, Huang L. Monoclonal antibody and liposomes. Pharmacol Ther 1985;28:341-365.
24. Hughes BJ, Kennel SJ, Lee R, Huang L. Monoclonal antibody targeting of liposomes to mouse lung in vivo. Cancer Res 1989;49:6214-6220.
25. Holmberg E, Maruyama K, Kennel S, Klibanov A, Torchilin V, Ryan U, et al. Target-specific binding of immunoliposomes in vivo. J Liposome Res 1990;1:393-406.
26. Phillips NC, Tsoukas C. Immunoliposome targeting to CD4+ cells in human blood. Cancer Detect Prev 1990;14: 383-390.
27. Hospenthal DR, Rogers AL, Beneke ES. Effect of attachment of anticandidal antibody to the surfaces of liposomes encapsulating amphotericin B in the treatment of murine candidiasis. Antimicrob Agents Chemother 1989;33:16-18.
28. Maruyama K, Kennel S, Huang L. Lipid composition is important for highly efficient target binding and retention of immunoliposomes. Proc Natl Acad Sci USA 1990; 87:5744-5748.
29. van Etten EWM, ten Kate MT, Stearne LET, Bakker-Woudenberg IAJM. Amphotericin B liposomes with prolonged circulation in blood: in vitro antifungal activity, toxicity, and efficacy in systemic candidiasis in leukopenic mice. Antimicrob Agents Chemother 1995;39:1954-1958.
30. Kohno S, Otsubo T, Tanaka E, Maruyama K, Hara K. Amphotericin B encapsulated in polyethylene glycol-immunoliposomes for infectious diseases. Advan Drug Del Rev 1997;24:325-329.
31. Otsubo T, Maruyama K, Maesaki S, Miyazaki Y, Tanaka E, Takizawa T, et al. Long-circulating immunoliposomal amphotericin B against invasive pulmonary aspergillosis in mice. Antimicrob Agents Chemother 1998;42:40-44.
32. Sunamoto J, Goto M, Tida T, Hara K, Saito A, Tomonaga A. Unexpected tissue distribution of liposomes coated with amylopectin derivatives and successful use in the treatment of experimental Legionnaires disease. In: Gregoriadis G, Poste G, Senior J, Trouet A (eds) Receptor-mediated targeting of drugs. New York: Plenum Press,1983:359.
33. Kohno S, Miyazaki T, Yamaguchi K, Tanaka H, Hayashi T, Hirota M, et al. Polysaccharide-coated liposome with antimicrobial agents against intracytoplasmic pathogen and fungus. J Bioactive Compatible Polymers 1988;3:137-147.
34. Giurgea-Marison L, Toubeau G, Laurent G, Heuson-Stiennon J, Tulkens PM. Impairment of lysosome-pinocytic vesicle fusion in rat kidney proximal tubules after treatment with gentamicin at low doses. Toxicol Appl Pharmacol 1986;86:271-285.
35. Laurent G, Garlier MB, Rollman B, Van Hoof F, Tulkens P. Mechanism of aminoglycoside-induced lysosomal phospholipidosis: in vitro and in vivo studies with gentamicin and amikacin. Biochem Pharmacol 1982;31: 3861-3870.
36. Cleary JD, Hayman J, Sherwood J, Lasala GP, Piazza-Hepp T. Amphotericin B overdose in pediatric patients with associated cardiac arrest. Ann Pharmacother 1993;27: 715-719.
37. Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis 1996;22:S133-S144.
38. Lopez-Berestein G, Mehta R, Hopfer RL, Mills K, Kasi L, Mehta K, et al. Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. J Infect Dis 1983; 147:939-945.
39. Proffitt RT, Satorius A, Chiang SM, Sullivan L, Adler-Moore JP. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J Antimicrob Chemother 1991;28(suppl B):49-61.
40. Pisarik L, Joly V, Jullien S, Carbon C, Yeni P. Reduction of free amphotericin B acute toxicity in mice after intravenous administration of empty liposomes. J Infect Dis 1990; 161:1042-1044.
41. Longuet P, Joly V, Amirault P, Seta N, Carbon C, Yeni P. Limited protection by small unilamellar liposomes against the renal tubular toxicity induced by repeated amphotericin B infusion in rats. Antimicrob Agents Chemother 1991;35:1303-1308.
42. Meunier F, Prentice HG, Ringden O. Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J Antimicrob Chemother 1991;28(suppl B):83-91.
43. Rinden O, Meunier F, Tollemar J, Ricci P, Tura S, Kuse E, et al. Efficacy of amphotericin B encapsulated liposome (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother 1991;28(suppl B):73-82.
44. Levine S, Walsh T, Martinez A, Eichacker PQ, Lopez-Berestein G, Natanson C. Cardiopulmonary toxicity after liposomal amphotericin B infusion. Ann Intern Med 1991;114:664-666.
45. Coker RJ, Murphy SM, Harris JRW. Experience with liposomal amphotericin B (AmBisome) in cryptococcal meningitis in AIDS. J Antimicrob Chemother 1991;28 (suppl B):105-109.
46. Cofrancesco E, Boschetti C, Anna M, Bargiggia C, Tortorano AM, Cortellaro M, et al. Efficacy of liposomal amphotericin B of Fusarium infection in a leukemic patient. Haematologica 1992;77:280-283.
47. Munckhof W, Jones R, Tosolini FA, Marzec A, Angus P, Grayson ML. Cure of Rhizopus sinusitis in a liver transplant recipient with liposomal amphotericin B. Clin Infec Dis 1993;16:183.
48. Janoff AS, Boni LT, Popescu MC, Minchey SR, Cullis PR, Madden TD, et al. Unusual lipid structures selectively reduce the toxicity of amphotericin B. Pro Natl Acad Sci USA 1988;85:6122-6126.
49. Clark JM, Whitney RR, Olsen SJ, George RJ, Swerdel MR, Kunselman L, et al. Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob Agents Chemother 1991;35:615-621.
50. Perkins WR, Minchey SR, Boni LT, Swenson CE, Popescu MC, Pasternack RF, et al. Amphotericin B-phospholipid interaction responsible for reduced mammalian cell toxicity. Biochim Biophys Acta 1992;1107:271-282.
51. Janoff AS, Perkins WR, Saletan SL, Swenson CE. Amphotericin B lipid complex (ABLC): a molecular rationale for the attenuation of amphotericin B related toxi cities. J Liposome Res 1993;3:451-472.
52. Brajtburg J, Bolard J. Carrier effects on biological activity of amphotericin B. Clin Microbiol Rev 1996;9:512-531.
53. Hay RJ. Antifungal drugs on the horizon. J Am Acad Dermatol 1994;31:S82-S85.
54. Lopez-Berestein G, Mehta R, Hopfer RL, Mills K, Kasi L, Mehta K, et al. Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. J Infect Dis 1983; 147:939-945.
55. de Marie S. Liposome and lipid-based formulations of amphotericin B. Leukemia 1996;10:S93-S96.
56. Graybill JR, Craven PC, Taylor RL, Williams DM, Magee WE. Treatment of murine cryptococcosis with liposome-associated amphotericin B. J Infect Dis 1982;145:748-752.
57. Tollemar J, Hockerstedt K, Ericzon B-G, Jalanco H, Ringden O. Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. A randomized, placebo-controlled study. Transplantation 1995;59:45-50.
58. Gilbert BE, Wyde PR, Wilson SZ. Aerosolized liposomal amphotericin B for treatment of pulmonary and systemic Cryptococcus neoformans infections in mice. Antimicrob Agents Chemother 1992;36:1466-1471.
59. Janoff AS, Boni LT, Popescu MC, Minchey SR, Cullis PR, Madden TD, et al. Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc Natl Acad Sci USA 1988;85:6122-6126.
60. Clark JM, Whitney RR, Olsen SJ, George RJ, Swerdel MR, Kunselman L, et al. Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob Agents Chemother 1991;35:615-621.
61. Mitsutake K, Kohno S, Miyazaki Y, Noda T, Miyazaki H, Miyazaki T, et al. In vitro and in vivo antifungal activities of liposomal amphotericin B, and amphotericin B lipid complex. Mycopathologia 1994;128:13-17.
62. Sharkey PK, Graybill JR, Johnson ES, Hausrath SG, Bollard RP, Kolokathis A, et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996;22:315-321.
63. Gonzalez CE, Couriel DR, Walsh TJ. Disseminated zygomycosis in a neutropenic patient: successful treatment with amphotericin B lipid complex and granulocyte colony-stimulating factor. Clin Infect Dis 1997;24:192-196.
64. Stevens DA. Overview of amphotericin B colloidal dispersion (Amphocil). J Infect 1994;28(suppl I):45-49.
65. Hosteller JS, Clemons KV, Hanson LH, Stevens DA. Efficacy and safety of amphotericin B colloidal dispersion compared with those of amphotericin B deoxycholate suspension for treatment of disseminated murine cryptococcosis. Antimicrob Agents Chemother 1992;36:2656-2660.
66. Clemons KV, Stevens DA. Comparison of Fungizone, Amphotec, AmBisome, and Abelcet for treatment of systemic murine cryptococcosis. Antimicrob Agents Chemother 1998;42:899-902.
67. Sanders SW, Buchi KN, Goddard MS, Lang JK, Tolman KG. Single-dose pharmacokinetics and tolerance of a cholesteryl sulfate complex of amphotericin B administered to healthy volunteers. Antimicrob Agents Chemother 1991;35:1029-1034.
68. Valero G, Graybill JR. Successful treatment of cryptococcal meningitis with amphotericin B colloidal dispersion: report of four cases. Antimicrob Agents Chemother 1995; 39:2588-2590.
69. Anaissie EJ, Mattiuzzi GN, Miller CB, Noskin GA, Gurwith MJ, Mamelok RD, et al. Treatment of invasive fungal infections in renally impaired patients with amphotericin B colloidal dispersion. Antimicrob Agents Chemother 1998;42:606-611.
70. Oppenheim BA, Herbrecht R, Kusne S. The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin Infect Dis 1995;21:1145-1153.
71. Seki J, Sasaki H, Doi M, Yoshikawa H, Takahashi Y, Amane S, et al. Lipid nano-sphere (LNS), a protein-free analogue of lipoproteins, as a novel drug carrier for parenteral administration IV. J Control Release 1994;28:352-353.
72. Kohno S, Otsubo T, Hara K, Tomii Y, Seki J. A new antifungal drug delivery system, lipid nano-sphere encapsulating amphotericin B (LNS-AmB), its evaluation in the rat model of invasive pulmonary aspergillosis [abstract 109]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1995:131.
73. Hossain MA, Maesaki S, Kakeya H, Noda T, Yanagihara K, Sasaki E, et al. The efficacy of NS-718, a novel lipid nanosphere-encapsulated amphotericin B against Cryptococcus neoformans. Antimicrob Agents Chemother 1998;42:1722-1725.
74. Mehta RT, Hopfer RL, Gunner LA, Juliano RL, Lopez-Berestein G. Formulation, toxicity, and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic fungal infection. Antimicrob Agents Chemother 1987;31:1897-1900.
75. Mehta RT, Hopfer RL, McQueen T, Juliano RL, Lopez-Berestein G. Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections. Antimicrob Agents Chemother 1987;31:1891-1903.
76. Miyamoto H, Ogura Y, Hashizoe M, Kunou N, Honda Y, Ikada Y. Biodegradable scleral implant for intravitreal controlled release of fluconazole. Curr Eye Res 1997;16:939-935.
77. Wong JP, Stadnyk LL, Saravolac EG. Enhanced protection against respiratory influenza A infection in mice by liposome-encapsulated antibody. Immunology 1994;81:280-284.
78. Nagai T, Nishibe Y, Makino Y, Tomimori T, Yamada H. Enhancement of in vivo anti-influenza virus activity of 5,7,4′-trihydroxy-8-methoxyflavone by drug delivery systern using hydroxypropyl cellulose. Biol Pharm Bull 1997; 20:1082-1085.
79. Kamps JAAM, Swart PJ, Morselt HW, Pauwels R, Bethune M-PD, Clercq ED, et al. Preparation and characterization of conjugates of (modified) human serum albumin and liposomes: drug carriers with an intrinsic anti-HIV activity. Biochim Biophys Acta 1996;1278:183-190.
80. Philips NC, Tsoukas C. Immunoliposome targeting to CD4+ cells in human blood. Cancer Detect Prev 1990;14: 383-390.
81. Bender AR, von Briesen H, Creuter J, Duncan IB, Rubsamen-Waigmann H. Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/macrophages in vitro. Antimicrob Agents Chemother 1996;40:1467-1471.
82. Kuppermann BD, Assil KK, Vuong C, Besen G, Wiley CA, Clercq ED, Bergeron-Lynn G, Connor JD, Pursley M, Mungia D, Freeman WR. Liposome-encapsulated (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for long-acting therapy of viral retinitis. J Infect Dis 1996;173:18-23.
83. Taskintuna I, Banker AS, Flores-Aguilar M, Bergeron-Lynn G, Aldern KA, Hostetler KY, et al. Evaluation of a novel lipid prodrug for intraocular drug delivery: effect of acyclovir diphosphate dimyristoylglycerol in a rabbit model with herpes simplex virus-1 retinitis. Retina 1997;17:57-64.
84. Banerjee G, Nandi G, Mahato SB, Pakrashi A, Basu MK. Drug delivery system: targeting of pentamidines to specific sites using sugar grafted liposomes. J Antimicrob Chemother 1996;38:145-150.
85. Rodrigues JM Jr, Bories C, Emery I, Fessi H, Devissaguet JP, Liance M. Development of an injectable formulation of albendazole and in vivo evaluation of its efficacy against Echinococcus multilocularis metacestode. Int J Parasitol 1995;25:1437-1441.